Zhang Yonghui, Cai Jinyan, Ruan Hanli, Pi Huifang, Wu Jizhou
Faculty of Pharmaceutical Sciences, Tongji Medical College of Huazhong University of Science and Technology, Hangkong Road 13#, Wuhan 430030, China.
J Ethnopharmacol. 2007 Nov 1;114(2):141-5. doi: 10.1016/j.jep.2007.05.022. Epub 2007 Jun 3.
Different doses of kinsenoside, a high yielding constituent from Anoectochilus roxburghii, was orally administered to further investigate its biological activity and pharmacological mechanisms that involve in the hypoglycemic effect on streptozotocin (STZ) diabetic rats. Our study showed that this compound exhibited significantly antihyperglycemic activity at the dose of 15mg/kg body weight, which is speculated to be partially attributed to modulating the activity of enzymatic antioxidants, scavenging free radicals, and reducing the content of factor NO. Much more intact beta cells in the islets of Langerhans with denser insulin in kinsenoside-treated groups than the negative control were observed, which greatly supported the morphological and functional elucidation. These results displayed that kinsenoside could be useful for repairing beta cells in pancreatic islet injury as well as improving its function. The OGTT evidenced that this compound could promote the glucose tolerance of acute glucose increase in both diabetic and normal healthy rats.
将不同剂量的金线莲苷（一种从金线莲中高产的成分）口服给药，以进一步研究其生物活性和药理机制，这些机制涉及对链脲佐菌素（STZ）诱导的糖尿病大鼠的降血糖作用。我们的研究表明，该化合物在体重15mg/kg的剂量下表现出显著的抗高血糖活性，推测这部分归因于调节酶促抗氧化剂的活性、清除自由基以及降低因子NO的含量。与阴性对照组相比，在金线莲苷处理组的胰岛中观察到更多完整的β细胞，胰岛素密度更高，这极大地支持了形态学和功能方面的阐释。这些结果表明，金线莲苷可用于修复胰岛损伤中的β细胞以及改善其功能。口服葡萄糖耐量试验（OGTT）证明，该化合物可促进糖尿病大鼠和正常健康大鼠对急性血糖升高的葡萄糖耐受性。
